- Home
- CANF vs OVBC Comparison
CANF vs OVBC Comparison
Compare CANF & OVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- OVBC
- Stock Information
- Founded
- CANF 1994
- OVBC 1872
- Country
- CANF Israel
- OVBC United States
- Employees
- CANF N/A
- OVBC N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- OVBC Major Banks
- Sector
- CANF Health Care
- OVBC Finance
- Exchange
- CANF Nasdaq
- OVBC Nasdaq
- Market Cap
- CANF 7.9M
- OVBC N/A
- IPO Year
- CANF N/A
- OVBC N/A
- Fundamental
- Price
- CANF $1.20
- OVBC $35.50
- Analyst Decision
- CANF Strong Buy
- OVBC
- Analyst Count
- CANF 2
- OVBC 0
- Target Price
- CANF $14.00
- OVBC N/A
- AVG Volume (30 Days)
- CANF 413.8K
- OVBC 11.6K
- Earning Date
- CANF 04-29-2025
- OVBC 04-28-2025
- Dividend Yield
- CANF N/A
- OVBC 2.59%
- EPS Growth
- CANF N/A
- OVBC N/A
- EPS
- CANF N/A
- OVBC 2.32
- Revenue
- CANF $674,000.00
- OVBC $59,506,000.00
- Revenue This Year
- CANF $461.72
- OVBC N/A
- Revenue Next Year
- CANF N/A
- OVBC N/A
- P/E Ratio
- CANF N/A
- OVBC $15.29
- Revenue Growth
- CANF N/A
- OVBC 5.20
- 52 Week Low
- CANF $1.22
- OVBC $19.35
- 52 Week High
- CANF $4.69
- OVBC $32.81
- Technical
- Relative Strength Index (RSI)
- CANF 37.12
- OVBC 70.59
- Support Level
- CANF $1.22
- OVBC $28.50
- Resistance Level
- CANF $1.82
- OVBC $30.58
- Average True Range (ATR)
- CANF 0.13
- OVBC 1.92
- MACD
- CANF -0.02
- OVBC 0.58
- Stochastic Oscillator
- CANF 3.13
- OVBC 84.12
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).